机构:[1]National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, Chongqing Collaborative Innovation Center of Targeted and Innovative Therapeutics, College of Pharmacy & International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, China[2]Integrative Cancer Center & Cancer Clinical Research Center, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, School of Medicine University of Electronic Science and Technology of China, Chengdu 610041, China四川省肿瘤医院
Background. Cancer remains a major clinical challenge because of the lack of effective drug for its treatment. To find out novel cancer chemotherapeutic molecules, we explored the anticancer effect of novel imidazopyridine compound 9i and also investigated the underlying molecular mechanism.Methods. Human cervical cancer cell (HeLa) viability was measured by an MTT assay after treatment with compound 9i. Clonogenicity of HeLa cells was investigated by an in vitro colony formation assay. Cell death was visualized by propidium iodide (PI) staining. Fluorescence-activated cell sorting (FACS) was used to determine apoptosis and mitochondrial membrane potential in HeLa cells. The expression level of apoptosis-related proteins was also determined by western blot. Results. Compound 9i suppressed HeLa cell viability in a time- and dose-dependent manner. Compound 9i induced mitochondrial outer membrane permeabilization (MOMP), activated caspase cascade, and finally resulted in apoptosis.Conclusion. Compound 9i induces mitochondrial pathway-mediated apoptosis in human cervical cancer cells, suggesting that 9i could be a potential lead compound to be developed as a cancer therapeutic molecule.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [NSFC 81873048]; Chongqing Research Program of Basic Research and Frontier Technology [cstc2018jcyjAX2019]; Science and Technology Research Program of the Chongqing Municipal Education Commission [KJQN201801304, KJQN201901331]; Scientific Research Foundation of the Chongqing University of Arts and Sciences [2017RBX11, 2017ZBX07, 2017ZBX08]
第一作者机构:[1]National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, Chongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, Chongqing Collaborative Innovation Center of Targeted and Innovative Therapeutics, College of Pharmacy & International Academy of Targeted Therapeutics and Innovation, Chongqing University of Arts and Sciences, Chongqing 402160, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Juanli Wang,Hong Wu,Guiting Song,et al.A Novel Imidazopyridine Derivative Exerts Anticancer Activity by Inducing Mitochondrial Pathway-Mediated Apoptosis[J].BIOMED RESEARCH INTERNATIONAL.2020,2020:doi:10.1155/2020/4929053.
APA:
Juanli Wang,Hong Wu,Guiting Song,Donglin Yang,Jiuhong Huang...&Chuan Xu.(2020).A Novel Imidazopyridine Derivative Exerts Anticancer Activity by Inducing Mitochondrial Pathway-Mediated Apoptosis.BIOMED RESEARCH INTERNATIONAL,2020,
MLA:
Juanli Wang,et al."A Novel Imidazopyridine Derivative Exerts Anticancer Activity by Inducing Mitochondrial Pathway-Mediated Apoptosis".BIOMED RESEARCH INTERNATIONAL 2020.(2020)